LiberiaTuberculosis profile
Population  2014 4.4 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3 (2.2–4) 68 (49–90)
Mortality (HIV+TB only) 0.33 (0.28–0.39) 7.5 (6.3–8.8)
Prevalence  (includes HIV+TB) 22 (12–37) 510 (267–831)
Incidence  (includes HIV+TB) 14 (12–15) 308 (273–346)
Incidence (HIV+TB only) 2.1 (1.7–2.7) 49 (38–61)
         
Case detection, all forms (%) 37 (33–42)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
62 (11–110) 13 (3–22)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 105   74
Pulmonary, clinically diagnosed 552   0
Extrapulmonary 1 304   0
       
Total new and relapse 5 035    
Previously treated, excluding relapses 0    
Total cases notified 5 035    
Among 1 703 new cases:
46 (3%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 801 (56)
HIV-positive TB patients 402 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 214 (53)
HIV-positive TB patients on antiretroviral therapy (ART) 112 (28)
HIV-positive people screened for TB 161  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (40) 3 534
Previously treated cases, excluding relapse, registered in 2013 (64) 14
HIV-positive TB cases, all types, registered in 2013 (52) 795
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 3.9
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 2.3
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-26 Data: www.who.int/tb/data